The lancet oncology
-
The lancet oncology · Mar 2019
Randomized Controlled TrialDarolutamide for non-metastatic, castration-resistant prostate cancer.
-
The lancet oncology · Mar 2019
Randomized Controlled TrialAddition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Abiraterone acetate plus prednisone or prednisolone improves progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer. Radium-223 improves overall survival and delays the onset of symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases. We assessed concurrent treatment with abiraterone acetate plus prednisone or prednisolone and radium-223 in such patients. ⋯ Bayer.